Loading
Adipokines, Inflammation, and Metabolic Diseases / Regulation of Appetite and Obesity · Journal article
Journal of Endocrinology · August 6, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical mechanistic study in diet-induced obese mice showing that IL-2/anti-IL-2 complex and hyperbaric oxygen each reduce body weight and improve glucose homeostasis, with additive effects when combined, mediated partly by Treg expansion and reduced adipose tissue inflammation. The findings are promising for hypothesis generation but remain in animal models and do not yet support clinical translation.
Preclinical controlled intervention study in mice. Male C57BL/6 mice; per-group sample sizes not stated in abstract.. Intervention: IL-2/anti-IL-2 complex (IL-2C) and/or hyperbaric oxygen (HBO) therapy administered during 16-week diet period. Compared with: High-fat diet control; low-fat diet control.
Both IL-2C and HBO reduced HFD-induced body weight by 9–22% (P < 0.05) independent of caloric intake Glucose tolerance and insulin sensitivity improved with 20–25% reductions in IPGTT area under the curve and 30–35% reductions in IPITT area under the curve (P < 0.05) Combination therapy produced the most consistent metabolic improvements
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
While the mechanistic findings regarding Treg expansion and adipose tissue remodeling are of interest, this preclinical study cannot yet guide clinical practice. Human trials will be necessary to establish whether IL-2/anti-IL-2 complex and hyperbaric oxygen are safe and efficacious for obesity and metabolic dysfunction in patients.
Preclinical mechanistic study in mice demonstrating that IL-2/anti-IL-2 complex and hyperbaric oxygen expand Tregs and improve metabolic parameters; requires translation to human disease before clinical relevance can be assessed.
As stated by the source record.
Quoted from the source exactly as published.
While the mechanistic findings regarding Treg expansion and adipose tissue remodeling are of interest, this preclinical study cannot yet guide clinical practice. Human trials will be necessary to establish whether IL-2/anti-IL-2 complex and hyperbaric oxygen are safe and efficacious for obesity and metabolic dysfunction in patients.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Obesity is characterized by chronic inflammation and impaired glucose homeostasis. Regulatory T cells (Tregs) preserve immunometabolic balance, and their reduction contributes to metabolic disturbances. Although IL-2/anti-IL-2 complex (IL-2C) and hyperbaric oxygen (HBO) therapy expand Tregs, their combined effects on obesity remain unclear. Male C57BL/6 mice fed a low-fat diet (LFD) or high-fat diet (HFD) for 16 weeks and treated with IL-2C and/or HBO. Both interventions significantly reduced HFD-induced body weight (9-22%, P < 0.05) independent of caloric intake, with no significant changes in LFD groups. Glucose tolerance and insulin sensitivity improved, showing significant reductions in IPGTT and IPITT area under the curve values (20-25% and 30-35%, respectively, P < 0.05) compared to the HFD control. Combination therapy produced the most consistent metabolic improvements. Histological analysis demonstrated reduced adipocyte hypertrophy and crown-like structures in epididymal adipose tissue (P < 0.05). Treatments restored CD4+FoxP3+ Tregs, suppressed pro-inflammatory M1 macrophages, and decreased hypoxia-inducible factor-1α expression (P < 0.05). Consistent with these findings, histological examination revealed tissue-specific structural remodeling, characterized by restored multilocular adipocytes in iBAT and reduced adipocyte hypertrophy in iWAT under HFD conditions. These findings suggest that IL-2C and HBO improve immunometabolic dysfunction associated with obesity, in parallel with favorable adipose tissue remodeling and metabolic adaptation. Thus, IL-2C and HBO may represent complementary therapeutic strategies for enhancing metabolic health.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.